Termination of the Tamsulosin Hydrochloride Technology License-Out Agreement with Boehringer Ingelheim
An individual event involving the termination, including in Europe and elsewhere and in Argentina, of the technology license-out agreement with Boehringer Ingelheim International GmbH for the tamsulosin hydrochloride OCAS formulation.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.